MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Marksans Pharma Limited announces final approval for Cetirizine Hydrochloride Tablets 5 mg and 10mg from US FDA.11-01-2022
11-01-2022
MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
In terms of the Company''s Code of Conduct to Regulate, Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the securities of Marksans Pharma Limited (the Company) for the designated persons of the Company will remain closed from Saturday, 1st January, 2022 till 48 hours after the declaration of unaudited financial results for the quarter ended 31st December, 2021. The date of declaration of financial results will be intimated separately in due course of time. Designated Persons of the Company and/or their immediate relatives shall not trade in the securities of the Company during the aforesaid period of closure of trading window.31-12-2021
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to above cited regulation(s) and other applicable provisions, the below mentioned call was held with Investors on December 21, 2021 with the investors through conference call.22-12-2021
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation for schedule of Conference Call with Seven Canyons Advisors17-12-2021
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Marksans Pharma Limited announces UK MHRA approval for Loperamide 2mg Hard Capsules.09-12-2021
MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate no. 1094 in lieu of old lost share certificate no. 49 in the name of Aditya Saran under folio no. A00107026-11-2021
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
we hereby provide below details of meeting wherein officials of the Company will be meeting a group of investors. Date Organiser Meeting Type 19th November, 2021 Ambit Investor Connect - NT Asset Management Video Conference18-11-2021
Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the above Regulation, we hereby provide below details of group meeting wherein officials of the Company will be meeting a group of investors. Date Organiser Meeting Type 17th November, 2021 Spark Capital Video Conference16-11-2021
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith Unaudited Financial Results of the Company for the quarter and half-year ended 30th September, 2021 published on 11th November, 2021 in the Business Standard (English) and Tarun Bharat (Marathi) newspapers.12-11-2021